Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, People's Republic of China.
Department of Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, People's Republic of China.
Clin Transl Oncol. 2019 Aug;21(8):1005-1013. doi: 10.1007/s12094-018-02014-6. Epub 2019 Jan 12.
To study the clinical significance of serum epidermal growth factor receptor (EGFR) gene mutation and serum tumor markers in the prediction of tyrosine kinase inhibitor (TKI) efficacy in patients with lung adenocarcinoma.
Ninety patients with pathologically diagnosed lung adenocarcinoma were enrolled. Further, 51 out of 90 patients received the EGFR-TKI therapy, oral gefitinib. The correlations among serum EGFR gene mutations in exons 18-21, serum tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 24-2 (CA24-2), carbohydrate antigen 125, carbohydrate antigen 15-3 as well as carbohydrate antigen 19-9 (CA19-9) levels, and EGFR-TKI efficacy were determined.
There was a high consistency of EGFR gene mutation rate between serum and tissue samples. The serum EGFR gene mutation rate in female patients or non-smokers was significantly higher than that in male patients or smokers, respectively. Serum CA19-9, CA24-2, and CEA levels were significantly correlated with serum EGFR mutation. After receiving gefitinib, the progression-free survivals (PFSs) of patients with high serum CEA level, high serum CA19-9 level, or serum EGFR gene mutation were significantly higher than those of normal patients, respectively. The PFSs were significantly prolonged in patients with EGFR gene mutation and high serum CEA level or patients with EGFR gene mutation and high serum CA19-9 level compared with those in patients with one abnormal biomarker and normal patients.
Combined detection of EGFR gene mutations as well as CA19-9 and CEA levels in peripheral blood can predict the efficacy of EGFR-TKI in the treatment of patients with lung adenocarcinoma.
研究血清表皮生长因子受体（EGFR）基因突变和血清肿瘤标志物对肺腺癌患者酪氨酸激酶抑制剂（TKI）疗效的预测意义。
收集 90 例经病理诊断为肺腺癌的患者，其中 51 例接受了 EGFR-TKI 治疗，口服吉非替尼。检测血清 EGFR 外显子 18-21 基因突变、癌胚抗原（CEA）、糖类抗原 24-2（CA24-2）、糖类抗原 125、糖类抗原 15-3、糖类抗原 19-9（CA19-9）等血清肿瘤标志物与 EGFR-TKI 疗效的相关性。
血清和组织标本 EGFR 基因突变率具有较高的一致性。女性患者或不吸烟者的血清 EGFR 基因突变率明显高于男性患者或吸烟者。血清 CA19-9、CA24-2 和 CEA 水平与血清 EGFR 突变显著相关。接受吉非替尼治疗后，血清 CEA 水平升高、血清 CA19-9 水平升高或血清 EGFR 基因突变患者的无进展生存期（PFS）明显高于正常患者，EGFR 基因突变且血清 CEA 水平升高或 EGFR 基因突变且血清 CA19-9 水平升高患者的 PFS 明显长于具有一个异常生物标志物和正常患者的患者。
联合检测外周血 EGFR 基因突变以及 CA19-9 和 CEA 水平可以预测 EGFR-TKI 治疗肺腺癌患者的疗效。
